Future Prospects of Organ Transplantation by Altinörs, Mehmet Nur
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books











The gap between organ demand and supply is an universal problem in organ and 
tissue transplantation therapy. The gap is growing in spite of efforts spent in medi-
cal, educational, social areas and mass media support. This reality has created the 
need for completely new therapeutic alternatives for the management of end-stage 
organ disease. The present research should continue in future aiming to discover 
systems and devices capable of totally replacing the traditional transplantation. On 
the other hand, a different progress in underway in transplantation. The indication 
for solid organ transplantation is to save life and promote quality of life. The new 
developing transplantations of composite tissue, uterus and face are performed 
with completely different indications. Facial defects caused by various insults cause 
serious functional and esthetic disorders, psychological and social problems. Facial 
transplant surgery is accomplished to overcome such problems. Uterus transplanta-
tion is emerging as an alternative to female infertility. Transplantation of composite 
tissue includes different organs. The main purpose of composite tissue transplanta-
tion is to restore reduced or completely lost functions and to increase the quality of 
life. Nerve regeneration must occur as a consequence of transplant to regain sensory 
and motor functions. It appears that the future of transplantation involves devel-
opments in two main streams; invention of completely new tools for solid organ 
transplantation and advances in the transplantation of different organs including 
uterus, face and composite tissue.
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1. Introduction
The idea of replacing a malfunctioning diseased organ by the same organ dates 
back to antiquity, but major inventions and successful practice of transplanting 
solid organs have occurred in the second half of the 20th century. Pioneering work 
in human-to-human organ transplantation started in the 1950’s and in following 
decade. Since then, improvements in surgical techniques, better postoperative 
management in the intensive care units, the introduction of brain death concept 
and its beneficial effect of enlarging the donor pool, a better understanding of 
the natural course of the various diseases leading to organ failure, new immu-
nosuppressive agents have all contributed to transplantation activities. Today 
organ transplantation is a definitive treatment for an end-stage disease with low 
morbidity and mortality rates. Efforts directed to the education of medical staff 
and the general public, controlled system of financial payment for the living 
donor, similarly gifting to deceased donor’s family, extending the donor criteria, 
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acceptance of paired organ donation, organ donation campaigns and media 
 support are among the other measures to promote transplantation.
2. Discussion
Organ transplantation is a definitive and curative treatment for end-stage 
organ disease. The preferred source of organs is from the deceased. Particularly 
in developing countries, organ harvesting is more from living donors. Although 
the morbidity and mortality rates for living donors are extremely low, completely 
healthy individuals are exposed to medical, surgical, psychological and sometimes 
to economic risks.
While organ transplantation will continue to be the definitive treatment for 
the present and foreseen future, the statistical evidence revealing the gap between 
demand and supply and the experience of the global medical community has clearly 
shown that even the centers with best figures of organ supply are far from meeting 
the growing need. Therefore the scientific world has arrived at a point to think and 
search for alternative solutions and different therapeutic modalities for end-stage 
organ diseases. An overview of the present state of organ transplantation suggests 
that future interest and work will be focused on three major points:
a. increasing the frequency, safety and outcome of traditional transplantation 
activities. This would cover research to discover ways of expanding donor pool, 
especially cadaveric, and innovative work for longer and safer preservation 
of harvested organs and methods that would help to obtain better graft and 
survival rates. Weissenbacher and associates have reported the beneficial effects 
of ex-vivo/ex-situ hypothermic and normothermic machine perfusion in the 
transplantation of liver, kidney, intestine and pancreas. The beneficial effects 
include viability, organ utilization and improved initial graft function. The 
authors have considered the potential role of normothermic regional perfusion 
to re-condition donors after circulatory death organs before retrieval. Machine 
perfusion presents superiority over the traditional cold preservation method. 
Since organ preservation is an essential aspect of the transplantation process, 
these  developments provide hope for better organ quality and longer viability [1].
In solid-organ transplant, cell therapy is used as an immunomodulation therapy 
or as a functioning graft. The beneficial effects of cell therapy in solid-organ trans-
plantation are long-term kidney allograft survival and avoiding the well-known 
adverse effects of immunosuppressive drugs. Cell-based therapy in solid organ 
transplant is indicated for the treatment of ischemic reperfusion injury, for the 
prevention of chronic allograft nephropathy and induction of long-term allograft 
tolerance. Immunoregulatory cells act when it is necessary for immune suppression 
and there are several mechanisms by many pharmacologic targets [2].
b. developments in relatively new, emerging transplantations including the 
uterus, face and composite tissue. Such transplantations are expected to be 
performed with increasing frequency.
c. the ultimate goal of producing completely new devices or bioartificial organs 
which eventually would replace organ transplantation and maintain immu-
nosuppressive free life. Nowadays may be considered as the transition period 
where devices can at least partially take over the functions of the failing organ 
and bridge patients to transplantation.
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3. Xenotransplantation
Xenotransplantation, not a new concept in this field, is a controversial issue. 
Xenotransplantation which means transplantation of an organ, tissue, or cells 
between two different species, has regained attention because of advantages such 
as rich source, the chance of planned, and multiple transplantations. The main 
disadvantages are the possibility of animal disease transmission, immunologic, and 
physiologic differences.
In the sixteenth- century animal blood has been transferred to humans. Skin, 
corneal and blood vessel xenotransplantations were the early attempts. The kidney 
was the first solid organ of xenotransplantation. Dr. Keith Reemtsma, working at 
Tulane University, performed 13 xenotransplants in the 1960’s using both chimpan-
zee kidneys on each surgery. Only one patient survived for nine months while the 
rest died within 4 to 8 weeks due to either infection or rejection. Dr. Thomas Starzl 
performed the first liver xenotransplant using baboons as donors [3].
In October 1984, orthotopic cardiac xenotransplantation on “ Baby Fae” was 
performed by Dr. Leonard Bailey and his co-workers. The recipient was a 12-day 
neonate harboring hypoplastic left heart syndrome. The donor was an immuno-
logically-selected baboon. The baby died on the 20th postoperative day. Neither 
humoral nor cellular rejection of the xenograft was noted [4].
Galactosyl-α-1-3, galactose [GAL] is the most important antigen in xenotrans-
plantation. GAL is expressed in most cells of all mammals except humans, including 
porcine. GAL is found in intestinal bacteria, and there are antibodies against GAL in 
humans. Antibodies to nonGAL antigens are still a problem. The primary methods 
to prevent hyperacute rejection are the elimination of antibodies by plasmapheresis 
and immunoadsorption and depletion or inhibition of complements [5].
In the last 30 years, researchers have determined that the pig is the most suitable 
animal for xenotransplantation. The reasons for this are short maturation time, the 
human similarity in size and physiological aspects, and low risk of animal disease 
transmission. Genetically modified pigs have been developed to overcome the 
molecular incompatibility between species. Another important step is the devel-
opment of “knockout” pigs lacking the 1,3 galactosyl transferase gene encoding 
enzymes responsible for immunologic expression. Genetic engineering techniques 
can be easily applied to create rejection-resistant pig organs [6].
Knockout pigs have contributed to prolonged survival particularly in heart and 
kidney transplantation. Survival of pig-to-nonhuman primate heterotopic heart, 
kidney, and islet xenotransplantation over 900 days, over 400 days, and over 
600 days respectively has been reported [7]. Bioartificial organs that contain pig 
cells or tissues have gained considerable clinical experience and the risks have been 
reduced [8]. For the time being, the indications of xenografting seem unclear but 
should be kept aside for exceptional cases.
4. Rare organ transplants
4.1 Composite tissue transplantation
When body structures composed of multiple tissues derived from ectoderm and 
endoderm is transplanted then the procedure is named composite tissue allotrans-
plantation. Such transplants are also known as “ vascular composite allografts”. 
The concept of composite tissue transplantation includes hand, face, larynx, joint, 
abdominal wall transplantations. This type of transplant has a life-changing nature, 
as the main goal is to restore reduced or completely lost functions and to increase 
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the quality of life. Unlike solid organ transplants, nerve regeneration must occur in 
the transplant to restore sensory and motor functions.
The first hand transplant was tried in Ecuador in 1964 with failure. The failure 
was believed to be associated with inadequate immunosuppression [9]. Dubernard 
and his coworkers transplanted the right distal forearm and hand from a deceased 
donor to a 48- year- old male patient who had had a traumatic amputation of 
the distal third of his right forearm. Motor and sensory recovery were evaluated 
as excellent six months postoperatively and no serious signs of rejection were 
observed [10].
The same group performed surgical intervention involving bone fixation, 
arterial and venous anastomosis, nerve suturing, tendon, and muscle joining in a 
33-year old, bilateral forearm amputated patient. They applied physical therapy, 
electrostimulation, and occupational therapy in the postoperative period. In the 
postoperative 15th month, they observed satisfactory sensory and motor improve-
ment as well as improvement in the quality of life. This procedure was the first 
human double-hand transplantation with satisfactory results [11]. It is generally 
believed that bilateral below-elbow amputation is the most accepted indication for 
hand transplantation.
In a study comparing the functional and psychosocial outcomes of hand 
transplantation and prosthesis options, upper extremity functions were globally 
evaluated with ARAT [Action Research Arm Test] and SHAP [Southampton Hand 
Assessment Procedure]. The study revealed that functional results are not signifi-
cantly different. The advantages of transplantation are that it provides sensory 
and self-perception in addition to providing motor activity. Complications due to 
immunosuppression pose a disadvantage in transplantation. However, if immu-
nosuppression is well tolerated, regeneration of an organ with its like is naturally 
an advantage. In bilateral below-elbow amputees, it is understood that the benefit 
is greater when the acquisition of motor and sensory functions is compared with 
the risks of immunosuppression. Unilateral amputees can compensate for many 
functional deficits by using healthy limbs and prostheses. Also, In addition, there 
is no need for a long-term rehabilitation program after prosthesis implantation, as 
in transplantation. For these reasons, the prosthesis option is a priority in patients 
with unilateral below-elbow amputees [12].
4.2 Facial transplant
Facial defects caused by congenital malformations, gunshot injuries, animal 
bites, burns, traumas, or tumors such as neurofibromatosis cause serious functional 
and esthetic disorders, psychological and social problems. Basic requirements for 
a successful face transplant are craniofacial and microsurgical techniques, triple 
immunosuppression therapy, intensive physical therapy, and psychological sup-
port initiated in the early postoperative period for functions such as smelling, 
eating, drinking, laughing and speaking. In surgery, maxillary and facial branches 
of the external carotid artery are used for arterial anastomoses. Facial, external 
jugular and thyrolingofacial veins are preferred for venous anastomoses. Vascular 
anastomoses are followed by nerve anastomoses. The most problematic aspects of 
surgery are prolonged anesthesia, excessive blood loss, and transfusions to replace 
this loss, complex vascular anatomy due to trauma and changes related to previous 
 reconstructive surgeries [13].
Since the surgical experience with facial transplantation is limited, there are 
no algorithms on long-term results, late complications and their management. 
In a study conducted to clarify these issues and to get the opinions of physicians 
experienced in face transplantation, the training of the recipient, how to define the 
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failure in facial transplant, approach to complications and their management were 
investigated. Approximately 30% of those who received a survey responded. While 
93.8% of the participants stated that facial transplant failure, 91.1% mortality, and 
78.8% chronic organ rejection are the points that should be discussed, the answers 
revealed that there is no consensus about the definition of mortality rates and facial 
transplantation. Also, it has been observed that even in centers with experience in 
facial transplantation, there are no protocols for the treatment of rejection in the 
chronic period [14].
The first partial facial transplant was performed in Amiens France with 
 success. The patient was a victim of dog bite thus losing lips, nose and, central 
cheeks. The patient had recovered sensory and motor for a long period of time [15]. 
Immunosuppressive therapy complications and graft rejection, which are com-
mon problems in all organ transplants, are valid in face transplantation, and also a 
case diagnosed with beta-cell lymphoma and eventually developing chronic graft 
rejection has been reported [16]. Squamous cell carcinoma developed in the fourth 
case of face transplant performed by Dr. Özkan and his associates. After treatment, 
severe infection, respiratory failure and allograft rejection developed. Despite the 
removal of the graft, the patient was lost [17].
Future progress in face transplantation can be achieved with the  contribution 
of different fields of science and technology. Naturally this holds true for the 
progress of other organ transplantations. These include tissue engineering, creation 
of functional autogenous-mucosal-cutaneous junctions, neural regeneration, 3-D 
printed bioresorbable scaffolds, and elimination of antigenic transplanted tissue 
[18]. The drawbacks of facial transplantation are the cost, relatively small number 
of potential recipients and only cadaveric donation.
4.3 Uterus transplant
Uterus transplantation has emerged as an alternative solution for female 
 infertility. The first success in uterine transplantation was to ensure pregnancy by 
replantation of the uterus and ovaries in dogs [19].
The first example of human application was a live uterine transplant in Saudi 
Arabia on April 2000, to a 26-year old woman who lost her uterus six years ago 
due to postpartum hemorrhage. The donor was 46-year old lady. The patient 
had acute vascular thrombosis 99 days after transplant and had a hysterectomy. 
Although acute thrombosis and infarction were detected in the vessels in macro-
scopic and microscopic examination of the excised uterus, no findings suggesting 
rejection were found [20]. An important milestone in uterine transplantation is 
the allograft uterine transplant performed to a 23-year-old woman diagnosed 
with Mayer-Rokitansky-Kuster-Hauser syndrome in 2011 at Akdeniz University, 
Turkey. Embryo transfer was provided 18 months after transplantation and live 
birth was not possible although clinical pregnancy was detected by transvaginal 
 ultrasound [21].
The first clinical applications in Sweeden were made with nine living donors. In 
2013, uterus transplantation was performed on a 23-year-old woman with congeni-
tal absence of uterus [Rokitansky syndrome] at Sahlgrenska University Hospital in 
Gothenburg, Sweeden. The donor was a living 61-year old lady. The patient, who 
had a menstruation on the 43rd day after the transplant, continued to have regular 
menstruation. One year after the transplant, a single embryo transfer resulted in 
pregnancy. Therefore, the triple immunosuppression was started. The patient, 
pregnant for 31 weeks and five days, was admitted to the hospital with complaints 
of preeclampsia and was taken to cesarean section due to abnormal cardiotocogra-
phy findings. A healthy male baby, with APGAR scores of 9,9,10 and with a weight 
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compatible [1775 gr] with gestational age, was born. Thus, the first live birth was 
achieved with the uterine transplantation method in the medical literature [22].
Uterine transplantation does not carry a vital indication. Medical, surgical, legal, 
ethical, psychological, and social aspects of the process are discussed in medical 
and related communities. Common requirements for recipient and donor are good 
general health, no history of infection and cancer in the last five years. The upper 
age limit for the recipient is 35–40 and 55–65 for the donor. In elderly women, it is 
believed that the vessels be affected by arteriosclerosis, probably due to the atrophic 
nature of the uterus. The effect of age on graft success is unknown. Among the 
peroperative problems is the long duration of surgical intervention, especially in 
the donor.
A characteristic of uterine transplantation is the removal of the transplanted 
uterus after one or two births to prevent the patient from immunosuppressive 
therapy for a longer period. This period is foreseen as an average of five years. 
Therefore, it is not particularly superior to prefer live donors. Besides, psychological 
problems that the recipient may feel against the donor are eliminated by the use of 
cadaver uterus. Ethical foundations of uterine transplantation are gathered under 
the name of Montreal criteria. Accordingly, six conditions should be fulfilled for the 
recipient, four conditions for the donor, and four conditions for the healthcare team 
performing the treatment [23].
5. Future prospects
5.1 Organ bioengineering and regenerative medicine
The field of tissue engineering is evolving rapidly and is opening new horizons 
for novel treatment opportunities. Tissue engineering and regenerative medicine 
includes artificial and biological materials.
Whole organ decellularization and recellularization have gained importance 
in recent years. Decellularization, as the name implies, means the removal of all 
cellular components from the organ and at the same time, the micro and macro 
anatomy of the extracellular matrix is preserved. These scaffolds are repopulated 
with patient- derived cells or stem cells to construct an individual specific organ. 
Consequently immunosuppression is no more needed. Bioreactors are used for 
decellularization and recellularization [24].
The technology used for organ bioengineering includes seeding cells on 
 supporting scaffolding materials. The cell-scaffold technology uses adult cells, 
various progenitor cells, and progenitor cells that may differentiate into specific 
adult cells. Bioreactors are used for uniform scaffold distribution, nutrient sup-
ply, and waste removal. The regeneration process takes place in the bioreactors 
and consequently, bioengineered tissues and organs can be harvested for analysis 
and implantation. Bioreactors facilitate, monitor, and control biochemical and 
 biophysical processes [25].
Mostly used scaffolds are decellularized allogeneic extracellular matrix which in 
turn is recellularized by autologous or stem cells. A wide variety of human tissues 
and organs have been decellularized for tissue engineering. These include cartilage, 
bone, skeletal muscle, tendon, adipose tissue, heart, arteries and veins, gingiva, cor-
nea, vocal folds, peripheral nerves, intestine, liver, pancreas, kidney, bladder, male 
and female reproductive systems, products of child birth and complex composite 
structures. Decellularization requires efficient removal of immunogenic cellular 
materials and maintenance of nonimmunogenic extracellular matrix. Human tis-
sues are harvested from cadavers and surgery. An advantageous point is the fact that 
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extracellular matrix derived from decellularization of a certain tissue may be used 
for tissue engineering of another tissue type [26].
Organ bioengineering aims to develop extracorporeal systems to compensate 
or completely replace the functions of a diseased organ. As an example, an extra-
corporeal method designed to substitute liver function should have the capacity to 
detoxify, synthesize, and regulate. The artificial liver support system has beneficial 
effects on the prognosis of patients with acute-on-chronic failure. These beneficial 
effects are generated by improving jaundice, ameliorating hemodynamic instability, 
reducing portal hypertension, and improving hepatic encephalopathy.
The de-and recellularization technique has been used to produce heart, lung, 
liver, kidney, and intestine. Despite of some laboratory success, the technique seems 
to be improved before clinical application [27].
5.2 Bioartificial organs
Dialysis treatment initiated the development of artificial organs. Bioartificial 
organs are aimed to fully compensate for the functions of a failing organ and they 
closely mimic human organs. Bioengineering is the mainstay of producing bioartifi-
cial organs, but an interdisciplinary approach including the contribution of material 
science, cell biology, mechanics, chemistry, informatics, surgery, computer science, 
physics, and medicine is required. Organ manufacturing, in its simplest definition, 
is producing bioartificial organs using living cells, other material, and advanced 
processing technologies. Organ manufacturing technologies are basically classified 
into three groups: fully automated, semi-automated, and hand- manipulated [28].
5.3 3D bioprinting
3D Bioprinting is a rapid prototyping and additive manufacturing technique 
used to produce artificial implants. Tissue and organ regeneration is one of the 
fields where 3D bioprinting is used. Bioprinting is layer-by-layer depositing of 
biological material with living cells using computer-aided transfer processes. 
Although whole vascularized organs for transplantation have not been produced by 
bioprinting yet, generation of the scaffold-free tubular trachea [29] and generation 
of scaffold-free nerve constructs using human gingiva-derived mesenchymal stem 
cell spheroids were reported [30]. 3-D bioprinting has been used in the production 
and transplantation of several organs including tracheal splints, vascular grafts, 
cartilaginous structures, heart tissue, multi-layered skin, and bone. The final goal 
is industrial bioproduction of individualized functional 3D organs for clinical 
application.
Nanotechnology has been useful for localized, sustained, and controlled delivery 
of drugs including immunosuppressive agents and clinically relevant biomarkers. 
Nano particles can also be used to deliver contrast agents to assist in delineating 
anatomy and therefore nanotechnology contributes to imaging of clinically relevant 
biomarkers and functional parameters for diagnosis and treatment [31].
Gene therapy has the potential to eliminate problems associated with immu-
nosuppression by allowing the production of immunomodulatory proteins in the 
donor grafts resulting in local immunosuppression. Gene therapy may also prevent 
chronic rejection [32].
5.4 Machine perfusion
Machine perfusion is a novel technique aimed to increased use of suboptimal 
grafts and consequently to enlarge donor pool. Large animal experiments have 
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revealed the superiority of machine preservation. The possibility of perfusing high-
risk livers consistently for 24 hours has been shown. During that period little evi-
dence of deterioration of the functional and histologic characteristics of the livers 
were noted. It has been claimed that perfusion may overcome the time limitations 
related with utilization of high risk livers. Another advantage of normothermic 
machine perfusion is measuring the functional parameters which give an idea about 
the viability of the organ [33] and this feature of machine perfusion is also valid for 
heart. The clinician may predict the risk of primary graft dysfunction. Repair and 
conditioning of thoracic organs are at experimental level for the time being. It has 
been reported that machine perfusion may also act as an immunoregulatory agent 
for lung [34]. Hypothermic and normothermic machine perfusion and controlled 
oxygenated rewarming keep kidney grafts functionally and metabolically active 
during preservation. Ex-vivo kidney perfusion has found clinical practice and on 
the other hand, preclinical results reveal that prolonged warm perfusion appears 
superior than a brief end-ischemic reconditioning as far as renal function and 
injury is concerned [35].
6. Specific organs
6.1 Liver
The liver has vital functions including plasma protein synthesis, hormone 
production, detoxification, decomposition of red blood cells, and regulation of 
glycogen storage. Due to these important functions, liver failure poses a threat to 
life. Historically, liver transplantation is second to kidney transplantation. Liver 
transplantation is a definitive treatment modality for acute liver failure and end-
stage chronic liver disease. The shortage of organ supply has initiated the usage of 
new therapeutic systems to reduce mortality and bridge patients to transplantation.
Albumin dialysis, plasmapheresis, column perfusion, and hybrid devices are 
among the instruments that have been used to compensate for liver function.
Artificial liver support systems may replace the failing functions of the organ 
and therefore time is gained for liver regeneration or transplantation. Artificial 
liver support systems are expected to detoxify, replenish plasma proteins, and 
reverse the inflammatory process. Among the artificial liver support systems, 
molecular adsorbent recirculating system [MARS], therapeutic plasma exchange 
[TPE], single- pass albumin dialysis [SPAD], and Prometheus can be named. MARS 
uses albumin dialysis to replace the detoxification function of the liver while TPE 
improves survival in patients with acute liver failure. MARS and TPE improve 
systemic hemodynamics and the grade of hepatic encephalopathy [36, 37].
Extracorporeal liver support systems are either cell- based [biological] or non- 
cell-based. Non- cell-based systems include high volume plasma exchange and 
albumin dialysis. Bioartificial liver systems improve neurologic function, reduce 
intracranial pressure and increase cerebral perfusion pressure Biological extracorpo-
real liver support systems aim to support the failing liver through detoxification [38].
Shen Yi and colleagues have performed a time-series-based meta-analysis of 
randomized clinical trials and observational studies that examined differences 
in mortality in acute-on-chronic liver failure patients treated with artificial liver 
support systems. The results revealed that an artificial liver support system had 
reduced the risk of short-term [1–3 months] mortality for patients with acute-on-
chronic liver failure by nearly 30%. As the results of the meta-analysis suggested, 
an artificial liver support system might reduce medium-term [6 month-1 year] 
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mortality risk by 30% and long-term [3 years] mortality risk by 50% in acute-on-
chronic liver failure patients [39].
The parenchymal cells of the liver are hepatocytes that constitute nearly 70–85% 
of the liver volume. Treatment of congenital metabolic disorders affecting the liver 
and acute liver failure using allogenic hepatocyte transplantation has been pro-
posed. The transplanted cells provide the impaired or missing hepatic function once 
engrafted into the recipient’s liver. Mature hepatocytes have been considered the 
most obvious cell type for liver cell transplantation. Some advantages of these cells 
have been noted. They are less invasive and less expensive not involving complex 
surgery, may be repeated in case of need, cryopreserved cells isolated from donor 
livers are immediately possible when required and native liver stays in place [40].
Demetriou AA et al. have shown favorable results on survival in patients with 
acute liver failure using an extracorporeal liver assist system. The system was com-
posed of 7 billion porcine hepatocytes within a hollow-fiber bioreactor. This phase 
II/III, prospective, randomized, multicenter, controlled trial included patients with 
fulminant-subfulminant hepatic failure or primary nonfunction [41].
6.2 Kidney
Long-term hemodialysis and peritoneal dialysis have been widely used in the 
treatment of end-stage renal failure patients. These treatment modalities have 
bridged thousands of patients to transplantation. The kidney is the first solid organ 
whose function could be replaced by an external device. Portable and wearable 
dialysis devices for the treatment of patients with end-stage kidney failure are being 
developed.
The evolution of devices designed to treat renal impaired patients has followed 
the sequence of portable artificial kidney [PAK], second- generation PAK, a wear-
able artificial kidney [WAK], and implantable bioartificial kidney [BAK]. All of 
these devices are to be smaller, lighter and intended for use outside the clinic. BAK 
can partially replace tubular function and it provides an extension to conventional 
dialysis systems and artificial kidneys by incorporating elements of living cellular 
and tissue function. The key features for the development of a bioengineered 
kidney require three main components. These are, cellular components, material 
engineering, and emerging technologies. Hollow membranes, extracellular matrix 
proteins, porous structures, and novel chemistries are included in material engi-
neering. Organoids, 3D printing, decellularized kidney and induced pluripotent 
stem cells compose the emerging technologies. Specialized kidney cells and stem 
cells constitute the cellular component. A bioartificial kidney is expected to be 
able to reproduce the metabolic, endocrine, immunomodulatory, and secretory 
 functions of a normal kidney [42].
Bioengineering and regenerative medicine also play a role in the efforts to 
construct an artificial kidney as a final target. New branches of engineering like 
artificial intelligence and machine learning for the real-time analysis of equipment 
alarm, dialysis parameters and patient-related data contribute to developments 
in this field. The problems encountered in the transplantation of recellularized 
whole kidney scaffolds are needed to efficiently repopulate the endothelium of the 
vascular network of the engineered kidney before implantation and optimal source 
of cells to repopulate an acellular kidney scaffold [43].
Generation of human- induced pluripotent stem cells derived kidney  organoids 
has been an important step in regenerative medicine and kidney organoids are 
expected to be used for disease modeling, drug discovery and ultimately be  applicable 
for transplant [44].
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6.3 Heart
Left ventricular assist device [LVAD] was developed as mechanical circulatory 
support [MCS] for heart failure patients. A long-term implantable continuous-flow 
LVAD named “the Heart II™ left Ventricular Assist system [Abbott Laboratories] 
has been approved by U.S. Food and Drug Administration for indications of desti-
nation therapy and bridging to transplantation. While the technology is advancing 
to achieve smaller size and eradication of drive lines, the expectation is to apply 
continuous-flow technology, which is in the experimental phase, to total heart 
replacement [45].
Implantation of a total artificial heart is indicated in end-stage heart failure 
patients. Acute hemodynamic restoration and clinical stabilization are achieved 
and the patient is then bridged to transplantation. It has been reported that a total 
artificial heart is associated with a post-transplantation survival rate very similar to 
national survival rates five years after transplantation [46] It has also been reported 
that total artificial heart patients have high rates of successful bridge-to-transplant 
and survival on par with biventricular assist device supported patients. The future 
objectives are decreased device size, continuous flow mechanisms, and use of 
bioprosthetic materials. Overcoming these hurdles will provide increased device 
longevity and decreased post-implant complications [47].
Taylor and associates have claimed that engineering a bioartificial heart has 
become a possibility. They have proposed a novel type of in vivo organ engineer-
ing utilizing pre-clinical models where decellularized hearts are heterotopically 
transplanted. The aim was to harness the capability of the body at least partly to 
repopulate the scaffold. The authors have added load and electric input and have 
posited that vascular and parenchymal cell maturation can occur. The authors 
have implanted porcine decellularized hearts acutely and chronically in living 
recipients in a heterotopic position and have demonstrated that short-term implan-
tation promotes endothelial cell adhesion to the vessel lumens and that long-term 
implantation also promotes tissue formation with evidence of cardiomyocytes and 
 endothelial cells present within the graft [48].
Pelletier et al. have reported that Rein-Heart-total artificial heart had shown safe 
and effective function in vivo and in vitro testing. The Rein-Heart has effectively 
replaced the native hearts’ functions in animals for up to two days [49].
There are obstacles to overcome before obtaining a bioartificial heart. These 
obstacles are, achieving adequate durability, longer than five years, minimizing 
thromboemboli and hemolysis, better efficiency, maintaining pulmonary-systemic 
circulatory balance and reduced size to accommodate in women and small 
 adolescents and children [50].
6.4 Lung
The structure of the lung is complex and lung decellularization is a complex 
process. The information is not sufficient. The most suitable cell types, media, and 
growth factors and how to provide the optimal conditions of ventilation, perfusion 
and oxygenation along the process of biofabrication are issues to be studied for 
further progress.
The key problem in producing a bioengineered lung is how to drive stem cell 
differentiation onto the different cell phenotypes. The role played by physical 
stimuli is also important in lung bioengineering because the cells within the organ 
are physiologically subjected to two main stimuli. These stimuli are ventilation and 
blood perfusion across the organ [51].
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Extracorporeal membrane oxygenation and mechanical can be used  temporarily 
as a bridge to transplantation. Experimental transplantation of bioartificial lung 
developed by perfusion decellularized synthetic scaffolds has been shown to 
provide gas exchange in vivo over a long period. The present level of achievements 
reveals that obtaining a transplantable artificial lung is not possible soon [52].
6.5 Pancreas
Artificial pancreas treatment is an alternative treatment that combines insulin 
pump and continuous glucose monitoring with a control algorithm to deliver 
insulin in a glucose- responsive manner. It is also named “closed-loop system” or 
“automated insulin delivery”. The artificial pancreas can be either insulin-only or 
dual hormone [glucagon] type. A systemic review and meta-analysis conducted by 
Bekiari and associates have shown that artificial pancreas systems are beneficial and 
safe treatment options for patients with type 1 diabetes. The authors have noted that 
the current research evidence on artificial pancreas systems is limited by incon-
sistency in outcome reporting, small sample size, and short follow-up duration of 
individual trials. So the future efforts should focus on such issues along with explor-
ing artificial pancreas use in relevant groups of people with type 2 diabetes such 
as those with inpatient hyperglycemia [53]. Other areas of interest for the future 
would be faster acting insulin in the artificial pancreas, increased accuracy, and 
reduced lag-time of continuous glucose monitoring. Self-learning adapting algo-
rithms will improve the level of automation and effectiveness. Cost-effectiveness in 
the general public is another issue to be taken into consideration [54].
7. Conclusion
The basic indication for solid organ transplantation is the treatment of end-stage 
diseases posing threat to life. Solid- organ transplantation evolved to be gold stan-
dard therapy and became a routine procedure with minimal morbidity and mortal-
ity figures. Despite the achievements in different fields of transplantation activities, 
the gap between demand and supply is growing due to an increased percentage of 
the elderly population, and the increase in the number patients that require organ 
transplant from which considerable number are lost while awaiting a suitable organ. 
The unmatched shortage of organs and life-long dependency on immunosuppres-
sive drugs and related complications of immunosuppression had warranted the 
development of alternative novel technologies for the repair or replacement of 
missing or malfunctioning organs.
Reproductive, functional, restorative, and psychologic indications have caused 
the emerging of transplanting different organs, namely face, extremity, and uterus. 
It is apparent that transplant procedures of these organs will be performed with 
increasing frequency in the future because successful results are closely associated 
with the accumulation of useful scientific data and experience.
The unmet demand for organs and the failure of immunosuppressive drugs 
to prolong long-term graft survival and a variety of complications associated 
with immunosuppression have caused the need for completely new therapeutic 
 modalities in the treatment of diseased and malfunctioning organs.
For the time being, human grafts and artificial devices are not capable of 
performing all the functions of vital organs. Artificial devices are beneficial in 
bridging patients to transplantation, or organ regeneration or as independent 
implantable units. The ultimate goal is to obtain human grafts to be totally 
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restored in all their structural and functional aspects, and artificial devices that 
can  completely replace native organs. The hurdles on the way can be overcome by 
close cooperation and integration of a wide variety of disciplines and technologies 
including tissue engineering, regenerative medicine, electronics, robotics, artificial 
intelligence, machine learning, 3D bioartificial printing, bioreactor technology, 
nano- technology, gene therapy, machine perfusion and cell biology. In light of 
the recent scientific developments, it can easily be assumed that reaching the goals 
mentioned is a matter of time. Tissue-engineered products and any kind of device 
expected to substitute totally human organs must certainly be safe, long durable, 
and non-immune. The cost-effectiveness and the ease of accessibility are issues to 
be managed in the future.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
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